Layer 1

POM to P switches: what made Maloff Protect and ellaOne a success?

Anna Maxwell: Embrace switches to encourage investment in pharmacy
Anna Maxwell: Embrace switches to encourage investment in pharmacy

C+D deputy editor Grace Lewis spoke to Anna Maxwell, CEO of medicines switching company Maxwellia, about what makes a successful POM to P change

Ms Maxwell has analysed over 30 medicine reclassifications, from prescription-only medicine (POM) to one available to purchase in pharmacies (P), she tells C+D. From ellaOne to Maloff Protect, she knows what makes a successful change.

In this podcast, she speculates on what other switches might be coming down the line, “beyond the cough, cold, pain and gastro categories”. She also explains why pharmacy teams should “embrace” medicine switches to encourage more investment in the sector.

You can listen to the podcast below. Alternatively, subscribe to C+D's podcasts on iTunes or by searching 'Chemist+Druggist podcast' on your preferred android podcast app.

Have you made the most of P medicines in your pharmacy?

David Moore, Locum pharmacist

Wasn't it Flomax? OTC Tamsulosin. Did no one see that the target audience were mostly over 60 and able to get it on a script for free?

A.S. Singh, Community pharmacist

Ella-One hardly a big seller. Price puts too many people off and too high risk to stock in pharmacies

Leon The Apothecary, Student

Plus can generally get it free instead.

Job of the week

Pharmacist Manager
Midlands, Cheshire & Dorset
Salary dependent upon experience